Last reviewed · How we verify
Placebo 4-weeks
Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.
At a glance
| Generic name | Placebo 4-weeks |
|---|---|
| Sponsor | Merz North America, Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance administered in blinded clinical trials to establish a baseline for comparison against active drug treatment. It allows researchers to distinguish genuine drug efficacy from placebo response effects and natural disease progression. The 4-week duration indicates this was the control arm duration in a Phase 3 trial conducted by Merz North America.
Approved indications
Common side effects
Key clinical trials
- Trial of Suvorexant for Sleep in Children With Autism (PHASE2)
- The Effect of NP-2006 on Sleep Quality and Health (NA)
- Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. (PHASE2)
- Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression (PHASE1, PHASE2)
- Toddler Biomarker of Nutrition Study (NA)
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Effectiveness of Combined Super Inductive System (SIS) Therapy With Therapeutic Exercise and Health Education in Lateral Elbow Tendinopathy (NA)
- Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |